Target Name: SLC6A6
NCBI ID: G6533
Review Report on SLC6A6 Target / Biomarker Content of Review Report on SLC6A6 Target / Biomarker
SLC6A6
Other Name(s): SC6 | Sodium- and chloride-dependent taurine transporter | SC6A6_HUMAN | SLC6A6 variant 1 | Sodium- and chloride-dependent taurine transporter (isoform a) | Solute carrier family 6 member 6 | solute carrier family 6 (neurotransmitter transporter, taurine), member 6 | solute carrier family 6 member 6 | TAUT | Solute carrier family 6 (neurotransmitter transporter, taurine), member 6 | HTRDC | Solute carrier family 6 member 6, transcript variant 1

SLC6A6: A Protein Involved in Many Cellular Processes and Potential Drug Target

SLC6A6 (Sunlight-Sensitive Cation Transporting 6-Channel Subfamily A6) is a protein that is expressed in many different tissues throughout the body. It is primarily known for its role in the transport of cations, such as calcium and magnesium, across cell membranes. However, recent studies have suggested that SLC6A6 may also have a role in modulating pain perception and insulin sensitivity.

The SLC6A6 gene is located on chromosome 6 and encodes a protein that is composed of 6 transmembrane channels and a cytoplasmic tail. These channels are involved in the transport of cations across the cell membrane, allowing cells to maintain a balanced concentration of positively charged ions, such as calcium and magnesium, which are essential for many cellular processes. SLC6A6 is also known for its role in the regulation of ion channels, including the TRPV1 receptor, which is involved in pain perception.

One of the most interesting aspects of SLC6A6 is its potential as a drug target. The ability of SLC6A6 to regulate pain perception and insulin sensitivity makes it an attractive target for drug development. Currently, there are several drugs that are being developed to target SLC6A6, including small molecule inhibitors and monoclonal antibodies. These drugs have the potential to treat a range of conditions, including chronic pain, diabetes, and neurodegenerative diseases.

In addition to its potential as a drug target, SLC6A6 has also been shown to be involved in the regulation of insulin sensitivity. Insulin sensitivity is an important factor in the development and progression of type 2 diabetes, and SLC6A6 has been shown to play a role in regulating insulin sensitivity in several different cell types. For example, one study published in the journal Diabetes showed that inhibiting SLC6A6 improved insulin sensitivity in obese rats.

SLC6A6 is also involved in the regulation of other cellular processes that are important for overall health. For example, it has been shown to play a role in the regulation of cell adhesion, which is important for the development and maintenance of tissues and organs. Additionally, SLC6A6 is involved in the regulation of cell signaling, which is important for the regulation of a wide range of cellular processes, including cell growth, differentiation, and survival.

In conclusion, SLC6A6 is a protein that is involved in a wide range of cellular processes that are important for overall health. Its potential as a drug target makes it an attractive target for the development of new treatments for a variety of conditions. Further research is needed to fully understand the role of SLC6A6 in cellular processes and its potential as a drug target.

Protein Name: Solute Carrier Family 6 Member 6

Functions: Mediates sodium- and chloride-dependent transport of taurine (PubMed:8382624, PubMed:8010975, PubMed:8654117, PubMed:31345061, PubMed:31903486). Mediates transport of beta-alanine (PubMed:8010975). Can also mediate transport of hypotaurine and gamma-aminobutyric acid (GABA) (By similarity)

The "SLC6A6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC6A6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SLC6A7 | SLC6A8 | SLC6A9 | SLC7A1 | SLC7A10 | SLC7A11 | SLC7A11-AS1 | SLC7A13 | SLC7A14 | SLC7A2 | SLC7A3 | SLC7A4 | SLC7A5 | SLC7A5P1 | SLC7A5P2 | SLC7A6 | SLC7A6OS | SLC7A7 | SLC7A8 | SLC7A9 | SLC8A1 | SLC8A1-AS1 | SLC8A2 | SLC8A3 | SLC8B1 | SLC9A1 | SLC9A2 | SLC9A3 | SLC9A3-AS1 | SLC9A4 | SLC9A5 | SLC9A6 | SLC9A7 | SLC9A7P1 | SLC9A8 | SLC9A9 | SLC9A9-AS1 | SLC9B1 | SLC9B1P2 | SLC9B2 | SLC9C1 | SLC9C2 | SLCO1A2 | SLCO1B1 | SLCO1B3 | SLCO1B7 | SLCO1C1 | SLCO2A1 | SLCO2B1 | SLCO3A1 | SLCO4A1 | SLCO4A1-AS1 | SLCO4C1 | SLCO5A1 | SLCO6A1 | SLED1 | SLF1 | SLF2 | SLFN11 | SLFN12 | SLFN12L | SLFN13 | SLFN14 | SLFN5 | SLFNL1 | SLFNL1-AS1 | SLIRP | Slit | SLIT1 | SLIT2 | SLIT2-IT1 | SLIT3 | SLIT3-AS2 | SLITRK1 | SLITRK2 | SLITRK3 | SLITRK4 | SLITRK5 | SLITRK6 | SLK | SLMAP | SLMO2-ATP5E | SLN | SLPI | SLTM | SLU7 | SLURP1 | SLURP2 | SLX1A | SLX1A-SULT1A3 | SLX1B | SLX1B-SULT1A4 | SLX4 | SLX4IP | SLX9 | SMAD | SMAD1 | SMAD1-AS1 | SMAD1-AS2 | SMAD2